Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

358
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
358
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

499
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
499
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

679
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
679
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials.

JCO precision oncology·2025
Same author

Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

IL-4 drives exhaustion of CD8<sup>+</sup> CART cells.

Nature communications·2024
Same author

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.

Nature medicine·2022
Same author

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.

Blood advances·2022
Same author

A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.

Cancer discovery·2020

Related Experiment Video

Updated: May 1, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

11.9K

Biological barriers and current strategies for modifying nanoparticle bioavailability.

Andrew M Prantner, Nathalie Scholler

    Journal of Nanoscience and Nanotechnology
    |April 16, 2014
    PubMed
    Summary

    Understanding how the body eliminates modified nanoparticles is crucial for clinical success. This review covers nanoparticle interactions with organs and the immune system, exploring strategies to improve bioavailability.

    More Related Videos

    Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
    17:16

    Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

    Published on: December 9, 2010

    12.3K
    Biofunctionalization of Magnetic Nanomaterials
    06:40

    Biofunctionalization of Magnetic Nanomaterials

    Published on: July 16, 2020

    4.1K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
    09:51

    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

    Published on: July 26, 2017

    11.9K
    Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
    17:16

    Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

    Published on: December 9, 2010

    12.3K
    Biofunctionalization of Magnetic Nanomaterials
    06:40

    Biofunctionalization of Magnetic Nanomaterials

    Published on: July 16, 2020

    4.1K

    Area of Science:

    • Biomedical Engineering
    • Materials Science
    • Immunology

    Background:

    • Nanoparticles are engineered with precise control over physical and chemical properties.
    • In vivo, nanoparticles interact with biological components, altering their surface and affecting fate.
    • Understanding these interactions is vital for translating nanomaterials into clinical use.

    Purpose of the Study:

    • To review the organs responsible for nanoparticle bioelimination (kidney, liver, spleen).
    • To examine innate immune system components (complement system, scavenger receptors) involved in nanoparticle recognition.
    • To present strategies for enhancing nanoparticle bioavailability.

    Main Methods:

    • Review of anatomical structures involved in nanoparticle clearance.
    • Analysis of innate immune mechanisms recognizing foreign nanoparticles.
    • Discussion of recent findings on surface modifications and material properties.

    Main Results:

    • Detailed anatomy of kidney, liver, and spleen in nanoparticle elimination.
    • Mechanisms of nanoparticle recognition by complement system and scavenger receptors.
    • Impact of surface modifications (e.g., PEG) and biomimetic approaches on bioavailability.

    Conclusions:

    • Effective nanoparticle translation requires understanding bioelimination pathways.
    • Innate immune system components play a key role in nanoparticle clearance.
    • Strategies like steric stabilization and biomimicry can improve nanoparticle bioavailability for therapeutic applications.